» Authors » Holger Schmid

Holger Schmid

Explore the profile of Holger Schmid including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 80
Citations 1965
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Meier F, Milek A, Rauch-Anderegg V, Benz-Fragniere C, Nieuwenboom J, Schmid H, et al.
PLoS One . 2020 Feb; 15(2):e0227342. PMID: 32074100
The transition to parenthood (TTP) is a stressful life event for most couples. Therefore, the way both partners jointly cope with stress (i.e., dyadic coping) is important for the prevention...
2.
Schmid H, Lederer S
Pol Arch Intern Med . 2019 Oct; 129(9):577-579. PMID: 31566588
No abstract available.
3.
Braun G, Linsenmaier U, Witt M, Schmid H
NDT Plus . 2017 Jun; 1(2):92-93. PMID: 28657036
No abstract available.
4.
Schmid H, Jelkmann W
Expert Opin Investig Drugs . 2016 Apr; 25(8):901-16. PMID: 27122198
Introduction: The main pillars for the treatment of chronic kidney disease (CKD) associated anemia are peptidic erythropoiesis stimulating agents (ESAs) and iron preparations. Both approaches benefit from long-term efficacy and...
5.
Khraishi M, Stead D, Lukas M, Scotte F, Schmid H
Clin Ther . 2016 Mar; 38(5):1238-49. PMID: 26988243
A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient access compared with biologics are a significant appeal of biosimilars....
6.
Schmid H
Expert Rev Hematol . 2015 Nov; 9(1):5-20. PMID: 26573694
Since more than two decades erythropoiesis-stimulating agents are the main pillar for treatment of anemia associated with chronic kidney disease. Methoxy polyethylene glycol-epoetin beta (MPG-EPO), also called continuous erythropoietin receptor...
7.
Schmid H, Lederer S
Expert Opin Pharmacother . 2015 Aug; 16(14):2179-91. PMID: 26293683
Introduction: Hyperphosphatemia is a frequent complication of chronic kidney disease and is associated with increased mortality. Despite side effects, risk of accumulation and high costs, phosphate binders (PBs) have become...
8.
Schmid H
Clinicoecon Outcomes Res . 2014 Jul; 6:319-30. PMID: 25050070
Background: Erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia therapy. Continuous erythropoietin receptor activator (CERA) is a highly effective, long-acting ESA developed for once-monthly dosing. A multitude of clinical studies...
9.
Haug S, Schaub M, Schmid H
Patient Educ Couns . 2014 Mar; 95(3):378-83. PMID: 24674150
Objective: To investigate the processes of change, demographic, health- and smoking-related predictors of both smoking cessation and smoking reduction in adolescents. Methods: Data were drawn from a sample of 755...
10.
Zotter S, Koch J, Schlachter K, Katzensteiner S, Dorninger L, Brunner J, et al.
Neuropediatrics . 2013 Aug; 44(6):346-53. PMID: 23921969
Background: In the majority of patients with Lyme neuroborreliosis (LNB), neurological symptoms are transient. The extent of neuropsychological and neuropsychiatric problems in children is not well researched. Objectives: The study...